Literature DB >> 29434339

Epidemiology and biomarker profile of pituitary adenohypophysial tumors.

Ozgur Mete1,2, Amber Cintosun1,2, Irwin Pressman3, Sylvia L Asa4,5.   

Abstract

Recent studies have reported the prevalence of pituitary tumors to be ~1/1000 population. Many are prolactin-producing tumors that are managed medically, however, the epidemiology of surgically resected pituitary adenohypophysial neuroendocrine tumors has not been reported in a large series with detailed characterization. We reviewed 1055 adenohypophysial tumors from 1169 transsphenoidal resections from the pathology files of University Health Network, Toronto, 2001-2016. Tumors were characterized by immunohistochemical localization of transcription factors (Pit-1, ERα, SF-1, Tpit), hormones (adrenocorticotropin, growth hormone, prolactin, β-thyrotropin, β-folliculotropin, β-luteotropin, α-subunit), and other biomarkers (keratins, Ki67, p27, FGFR4). Electron microscopy was used only for unusual lesions. In this cohort, 51.3% of patients were female; the average age was 51 years. Gonadotroph tumors represented 42.5%. Pit-1-lineage-tumors represented 29.9%; these were subclassified as growth-hormone-predominant (somatotroph/mammosomatotroph/mixed; 53%), prolactin-predominant (lactotroph/acidophil-stem-cell; 28%), thyrotrophs (2%), plurihormonal (14%), and not-otherwise-specified (3%). Corticotroph tumors represented 17.1%. Only 4.5% were null cell tumors and 0.5% were unusual plurihormonal tumors. In 5.5% the tumor was not characterized for technical reasons (sample size, fixation, necrosis or other artifact). All corticotroph and plurihormonal tumors were positive for keratins; others tumors showed variable negativity with highest rates in gonadotroph (37.1%) and null cell tumors (28.2%). Tumors with a Ki67 ≥ 3% comprised 60% of this cohort. Global loss of p27 was most frequent in corticotroph neoplasms, specifically those associated with elevated glucocorticoid levels. Corticotroph and lactotroph tumors were more common among females; gonadotroph tumors were more common among males. Younger patients had mainly corticotroph and Pit-1-lineage neoplasms, whereas older patients harbored mainly gonadotroph tumors. This represents one of the largest surgical series of morphologically characterized pituitary tumors reported to date and the first to include the routine use of transcription factors for tumor classification. The data provide the basis for clinicopathologic correlations that are helpful for prognostic and predictive patient management.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29434339     DOI: 10.1038/s41379-018-0016-8

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  28 in total

1.  Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.

Authors:  Ozgur Mete; Omalkhaire M Alshaikh; Amber Cintosun; Shereen Ezzat; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

2.  Spontaneous Pituitary Adenomas in Squirrel Monkeys (Saimiri sciureus).

Authors:  Gregory J Daggett; Jennifer S Wood; Sanjeev Gumber; Christopher J Pinelli
Journal:  Comp Med       Date:  2019-11-20       Impact factor: 0.982

Review 3.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

4.  Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers.

Authors:  Joao Paulo Almeida; Corbin C Stephens; Jennifer M Eschbacher; Michelle M Felicella; Kevin C J Yuen; William L White; Michael A Mooney; Anne Laure Bernat; Ozgur Mete; Gelareh Zadeh; Fred Gentili; Andrew S Little
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

5.  Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2021-04-17       Impact factor: 3.943

6.  An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.

Authors:  Omalkhaire M Alshaikh; Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2019-06       Impact factor: 3.943

Review 7.  Immunohistochemical Biomarkers in Pituitary Pathology.

Authors:  Sylvia L Asa; Ozgur Mete
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

8.  DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features.

Authors:  Maritza S Mosella; Thais S Sabedot; Tiago C Silva; Tathiane M Malta; Felipe Segato Dezem; Karam P Asmaro; Michael Wells; Abir Mukherjee; Laila M Poisson; James Snyder; Ana C deCarvalho; Tobias Walbert; Todd Aho; Steven Kalkanis; Paula C Elias; Sonir R Antonini; Jack Rock; Houtan Noushmehr; Margaret Castro; Ana Valeria Castro
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

Review 9.  Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification.

Authors:  Ashley B Grossman; Shereen Ezzat; Sylvia L Asa; Ozgur Mete; Michael D Cusimano; Ian E McCutcheon; Arie Perry; Shozo Yamada; Hiroshi Nishioka; Olivera Casar-Borota; Silvia Uccella; Stefano La Rosa
Journal:  Mod Pathol       Date:  2021-05-21       Impact factor: 7.842

10.  The silent variants of pituitary tumors: demographic, radiological and molecular characteristics.

Authors:  M E Torregrosa-Quesada; A García-Martínez; A Sánchez-Barbie; S Silva-Ortega; R Cámara; C Fajardo; C Lamas; I Aranda; A Pico
Journal:  J Endocrinol Invest       Date:  2021-01-21       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.